299 related articles for article (PubMed ID: 2083515)
21. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
22. A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia.
Steyn K; Weich HF; Vermaak WJ; Marais AD; Omar MA; Van Gelder AL; Fourie J; Kotze TJ; Stander I; Firth JC
S Afr Med J; 1991 Jun; 79(11):639-45. PubMed ID: 2047945
[TBL] [Abstract][Full Text] [Related]
23. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.
Bard JM; Luc G; Douste-Blazy P; Drouin P; Ziegler O; Jacotot B; Dachet C; De Gennes JL; Fruchart JC
Eur J Clin Pharmacol; 1989; 37(6):545-50. PubMed ID: 2693115
[TBL] [Abstract][Full Text] [Related]
24. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
Human JA; Ubbink JB; Jerling JJ; Delport R; Vermaak WJ; Vorster HH; Lagendijk J; Potgieter HC
Clin Chim Acta; 1997 Jul; 263(1):67-77. PubMed ID: 9247729
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
French JK; White HD; Greaves SC
N Z Med J; 1990 Feb; 103(883):41-3. PubMed ID: 2304688
[TBL] [Abstract][Full Text] [Related]
26. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Tikkanen MJ; Helve E; Nikkilä EA
Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684
[TBL] [Abstract][Full Text] [Related]
27. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and safety of simvastatin, a new cholesterol-lowering drug].
Mol MJ; Stuyt PM; Stalenhoef AF
Ned Tijdschr Geneeskd; 1989 Feb; 133(7):362-6. PubMed ID: 2927555
[TBL] [Abstract][Full Text] [Related]
29. Simvastatin in severe hypercholesterolaemia: a placebo controlled trial.
McDowell IF; Smye M; Trinick T; Shortt JA; Archibald MP; Trimble ER; Nicholls DP
Br J Clin Pharmacol; 1991 Mar; 31(3):340-3. PubMed ID: 2054273
[TBL] [Abstract][Full Text] [Related]
30. [Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
Brocard JJ; Keller U; Oberhänsli A; Riesen WF
Schweiz Med Wochenschr; 1991 Jun; 121(26):977-83. PubMed ID: 1862314
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
Golay A; Lehmann T; James R; Pometta D
Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
[TBL] [Abstract][Full Text] [Related]
32. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Branchi A; Rovellini A; Fiorenza AM; Sommariva D
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
Darioli R; Bovet P; Brunner HR; Bercher L
Schweiz Med Wochenschr; 1990 Jan; 120(4):85-91. PubMed ID: 2305221
[TBL] [Abstract][Full Text] [Related]
34. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
35. [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Berioli S; Bentivoglio M; Conti R; Osanna RA; Savino K; Zollino L; Corea L
Cardiologia; 1990 Apr; 35(4):335-40. PubMed ID: 2245435
[TBL] [Abstract][Full Text] [Related]
36. [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
Wenke K; Thiery J; Meiser B; Arndtz N; Seidel D; Reichart B
Z Kardiol; 1995 Feb; 84(2):130-6. PubMed ID: 7717016
[TBL] [Abstract][Full Text] [Related]
37. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation.
Barbir M; Rose M; Kushwaha S; Akl S; Mitchell A; Yacoub M
Int J Cardiol; 1991 Nov; 33(2):241-6. PubMed ID: 1743784
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
Ghizzoni G; Rusconi C; Faggiano P; Sabatini T; Oneglia C; Gardini A
Minerva Cardioangiol; 1993 Mar; 41(3):105-9. PubMed ID: 8510811
[TBL] [Abstract][Full Text] [Related]
39. [Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis].
Giannini SD; de Góes JM; Dereviack BE; Machado C; Forti N; Diament J
Arq Bras Cardiol; 1990 Jun; 54(6):407-14. PubMed ID: 2288531
[TBL] [Abstract][Full Text] [Related]
40. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia.
O'Brien RC; Simons LA; Clifton P; Cooper ME; Jennings GL; Jerums G; Nestel PJ; Sullivan D
Med J Aust; 1990 May; 152(9):480-3. PubMed ID: 2199801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
